Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

A quantitative systems pharmacology model of colonic motility with applications in drug development.

Das R, Wille L, Zhang L, Chen C, Winchester W, Selimkhanov J, Wykosky J, Apgar JF, Burke JM, Rogge M, Hua F, Vakilynejad M.

J Pharmacokinet Pharmacodyn. 2019 Oct;46(5):485-498. doi: 10.1007/s10928-019-09651-6. Epub 2019 Aug 20.

PMID:
31432345
2.

Glioblastoma cellular cross-talk converges on NF-κB to attenuate EGFR inhibitor sensitivity.

Zanca C, Villa GR, Benitez JA, Thorne AH, Koga T, D'Antonio M, Ikegami S, Ma J, Boyer AD, Banisadr A, Jameson NM, Parisian AD, Eliseeva OV, Barnabe GF, Liu F, Wu S, Yang H, Wykosky J, Frazer KA, Verkhusha VV, Isaguliants MG, Weiss WA, Gahman TC, Shiau AK, Chen CC, Mischel PS, Cavenee WK, Furnari FB.

Genes Dev. 2017 Jun 15;31(12):1212-1227. doi: 10.1101/gad.300079.117. Epub 2017 Jul 19.

3.

Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition.

Shen Y, Li J, Nitta M, Futalan D, Steed T, Treiber JM, Taich Z, Stevens D, Wykosky J, Chen HZ, Carter BS, Becher OJ, Kennedy R, Esashi F, Sarkaria JN, Furnari FB, Cavenee WK, Desai A, Chen CC.

Oncotarget. 2015 May 20;6(14):11751-67.

4.

A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma.

Wykosky J, Hu J, Gomez GG, Taylor T, Villa GR, Pizzo D, VandenBerg SR, Thorne AH, Chen CC, Mischel PS, Gonias SL, Cavenee WK, Furnari FB.

Cancer Res. 2015 Jan 15;75(2):394-404. doi: 10.1158/0008-5472.CAN-14-2004. Epub 2014 Nov 28.

5.

Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks.

Gomez GG, Wykosky J, Zanca C, Furnari FB, Cavenee WK.

Cancer Biol Med. 2013 Dec;10(4):192-205. doi: 10.7497/j.issn.2095-3941.2013.04.003. Review.

6.

Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA.

Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, Gomez G, Eskin A, Hwang K, Wang J, Masui K, Paucar A, Yang H, Ohashi M, Zhu S, Wykosky J, Reed R, Nelson SF, Cloughesy TF, James CD, Rao PN, Kornblum HI, Heath JR, Cavenee WK, Furnari FB, Mischel PS.

Science. 2014 Jan 3;343(6166):72-6. doi: 10.1126/science.1241328. Epub 2013 Dec 5.

7.

A kinome-wide RNAi screen in Drosophila Glia reveals that the RIO kinases mediate cell proliferation and survival through TORC2-Akt signaling in glioblastoma.

Read RD, Fenton TR, Gomez GG, Wykosky J, Vandenberg SR, Babic I, Iwanami A, Yang H, Cavenee WK, Mischel PS, Furnari FB, Thomas JB.

PLoS Genet. 2013;9(2):e1003253. doi: 10.1371/journal.pgen.1003253. Epub 2013 Feb 14.

8.

A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments.

Masui K, Gini B, Wykosky J, Zanca C, Mischel PS, Furnari FB, Cavenee WK.

Carcinogenesis. 2013 Apr;34(4):725-38. doi: 10.1093/carcin/bgt086. Epub 2013 Mar 1. Review.

9.

Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.

Fenton TR, Nathanson D, Ponte de Albuquerque C, Kuga D, Iwanami A, Dang J, Yang H, Tanaka K, Oba-Shinjo SM, Uno M, Inda MM, Wykosky J, Bachoo RM, James CD, DePinho RA, Vandenberg SR, Zhou H, Marie SK, Mischel PS, Cavenee WK, Furnari FB.

Proc Natl Acad Sci U S A. 2012 Aug 28;109(35):14164-9. doi: 10.1073/pnas.1211962109. Epub 2012 Aug 13.

10.

EphrinA1 is released in three forms from cancer cells by matrix metalloproteases.

Beauchamp A, Lively MO, Mintz A, Gibo D, Wykosky J, Debinski W.

Mol Cell Biol. 2012 Aug;32(16):3253-64. doi: 10.1128/MCB.06791-11. Epub 2012 Jun 11.

11.

Emerging insights into the molecular and cellular basis of glioblastoma.

Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF, Agarwalla PK, Chheda MG, Campos B, Wang A, Brennan C, Ligon KL, Furnari F, Cavenee WK, Depinho RA, Chin L, Hahn WC.

Genes Dev. 2012 Apr 15;26(8):756-84. doi: 10.1101/gad.187922.112. Review.

12.

Structural and functional characterization of monomeric EphrinA1 binding site to EphA2 receptor.

Lema Tomé CM, Palma E, Ferluga S, Lowther WT, Hantgan R, Wykosky J, Debinski W.

J Biol Chem. 2012 Apr 20;287(17):14012-22. doi: 10.1074/jbc.M111.311670. Epub 2012 Feb 23.

13.

Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations.

Wykosky J, Fenton T, Furnari F, Cavenee WK.

Chin J Cancer. 2011 Jan;30(1):5-12. Review.

14.

Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy.

Nitta M, Kozono D, Kennedy R, Stommel J, Ng K, Zinn PO, Kushwaha D, Kesari S, Inda MM, Wykosky J, Furnari F, Hoadley KA, Chin L, DePinho RA, Cavenee WK, D'Andrea A, Chen CC.

PLoS One. 2010 May 24;5(5):e10767. doi: 10.1371/journal.pone.0010767. Erratum in: PLoS One. 2011;6(4). doi:10.1371/annotation/9b9cc4ae-ad56-464f-ab97-59f096b5c0eb. Inda, Maria-del-Mar [added]; Wykosky, Jill [added].

15.

Escape from targeted inhibition: the dark side of kinase inhibitor therapy.

Wykosky J, Mukasa A, Furnari F, Cavenee WK.

Cell Cycle. 2010 May;9(9):1661-2. Epub 2010 May 16. No abstract available.

PMID:
20404502
16.

Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence.

Mukasa A, Wykosky J, Ligon KL, Chin L, Cavenee WK, Furnari F.

Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2616-21. doi: 10.1073/pnas.0914356107. Epub 2010 Jan 21.

17.

The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.

Wykosky J, Debinski W.

Mol Cancer Res. 2008 Dec;6(12):1795-806. doi: 10.1158/1541-7786.MCR-08-0244. Review.

18.

Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor.

Wykosky J, Palma E, Gibo DM, Ringler S, Turner CP, Debinski W.

Oncogene. 2008 Dec 11;27(58):7260-73. doi: 10.1038/onc.2008.328. Epub 2008 Sep 15.

19.

Interleukin-13 receptor alpha 2, EphA2, and Fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy.

Wykosky J, Gibo DM, Stanton C, Debinski W.

Clin Cancer Res. 2008 Jan 1;14(1):199-208. doi: 10.1158/1078-0432.CCR-07-1990.

20.

A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells.

Wykosky J, Gibo DM, Debinski W.

Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3208-18.

21.

EphA2 as a novel molecular marker and target in glioblastoma multiforme.

Wykosky J, Gibo DM, Stanton C, Debinski W.

Mol Cancer Res. 2005 Oct;3(10):541-51.

Supplemental Content

Loading ...
Support Center